Ligand Pharmaceuticals’ Post

APEIRON Biologics AG and invIOs INNOVATIVE IMMUNO-ONCOLOGY from #Vienna’s #lifesciences cluster hit the headlines: Ligand Pharmaceuticals acquired APEIRON Biologics AG for $100 million. APEIRON, known for its innovative approaches in immuno-oncology, received marketing approval from the European Medicines Agency for APN311 (dinutuximab beta, QARZIBA®) in 2017 for the treatment of high-risk neuroblastoma in patients aged twelve months and above. APEIRON shareholders are also entitled to additional consideration based on future commercial and regulatory events and to up to USD 28 million if QARZIBA® royalties exceed certain predetermined thresholds by either 2030 or 2034 respectively. Concurrently, Ligand has also committed to investing up to $4 million in invIOs Holding AG (“invIOs”), a spin-off of APEIRON. The proceeds will help invIOs to finance the research and development of three innovative early-stage immuno-oncology assets.   We would like to congratulate everyone involved on this outstanding success! It is remarkable when research findings are translated into medical practice, ultimately saving lives. This achievement is only possible when research institutions, clinics, companies of all sizes, social insurance providers, regulatory authorities, and other stakeholders collaborate constructively with a clear focus on patient well-being.

September 2, 2024 - Shenzhen TargetRx, Inc (“TargetRx”) announced that it has recently entered into a collaboration agreement with Simcere Zaiming, an innovative oncology company under Simcere Pharmaceutical Group (2096.HK), for the clinical-stage anti-tumor candidate drug, ALK/ROS1 dual receptor tyrosine kinase inhibitor TGRX-326. According to the terms of the agreement, Simcere Zaiming will acquire exclusive commercial rights to TGRX-326 in Mainland China. These rights include, but are not limited to, marketing promotion, strategy formulation and adjustment, as well as the right to obtain relevant benefits from TGRX-326. TargetRx will receive an upfront payment more than $20 million and will pay Simcere Zaiming fees for promotional services. For more details about this transaction, please visit: https://lnkd.in/gQAGrvB3

#BioBDHighlights On September 2, 2024, Simcere Pharmaceutical Group (2096.HK) announced that its innovative oncology drug subsidiary, Simcere Zaiming, has entered into a collaboration agreement with Shenzhen TargetRx, Inc. The partnership focuses on the clinical-stage oncology candidate drug, TGRX-326, a dual ALK/ROS1 receptor tyrosine kinase inhibitor. Under the terms of the agreement, Simcere Zaiming will obtain exclusive commercialization rights for TGRX-326 in mainland China, including but not limited to the promotion of TGRX-326, strategy formulation, adjustments, and the right to related benefits. TargetRx will receive an upfront payment of over $20 million and will also pay Simcere Zaiming a promotional service fee. #Oncology #Commercialization #pharmaceuticals #Partnership

Sullivan is financial advisors' counsel for A.G.P./Alliance Global Partners and Laidlaw & Company (U.K.) Ltd. in the $58.5 million announced merger agreement between Hepion Pharmaceuticals, Inc. and Pharma Two B Ltd. and the $2.9 million concurrent private placement of non-convertible senior notes. Hepion Pharmaceuticals (Nasdaq: HEPA) is a clinical-stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic diseases, hepatocellular carcinoma (“HCC”), and other chronic diseases. Pharma Two B Ltd. is a late-clinical stage private Israeli company that is developing P2B001, an innovative combination product candidate in development for the treatment of Parkinson’s Disease (“PD”). The Sullivan team consisted of David Danovitch and Aaron Schleicher with assistance from Jiayin Liao. To read the press release, click here: https://lnkd.in/emcSA7B7 #WhatsYourNext #CapitalMarkets

According to DelveInsight’s analysis, the market for PD-1 and PD-L1 inhibitors across the 7MM is projected to grow significantly through 2032. Leading companies like Buzzard Pharmaceuticals, AstraZeneca, Daiichi Sankyo US, and numerous others are developing innovative PD-1 and PD-L1 inhibitors expected to transform the market. Key inhibitors include Isunakinra, Spartalizumab, Dato-DXd, and many more, poised to redefine treatment approaches in the forecast period. Get detailed insights here: https://lnkd.in/gs3NNixy #PD1Inhibitors #PDL1Inhibitors #CancerTreatment #Biopharmaceuticals #MedicalInnovation #Isunakinra #DatoDXd #Spartalizumab #JEMPERLI #HealthcareMarket #OncologyResearch #MarketAnalysis

In 2023 we saw 55 ADCs enter the clinic for the first time bringing the number up to 331 assets that have entered the clinic! Some notable advancements: 🌏 Pfizer & Pyxis Oncology: PYX-201 🌏 Abmart & Multitude Therapeutics: AMT-116 🌏 Daiichi Sankyo, Inc. & Glycotope GmbH: DS-3939 🌏 Antengene: ATG-022 🌏 Bio-Thera Solutions: BAT8007 🌏 Sino Biopharmaceutical Limited: TQB2103 📈 The accompanying graph illustrates the dynamic progression of ADC assets in 2023, showcasing 12 ADCs advancing from phase 1/1-2 to phase 2. Additionally, 9 ADCs initiated phase 3 trials, marking significant progress from earlier-stage trials. #adc #adcs #antibodydrugconjugates #antibodydiscovery #trials #pharmaceutical #clinicalresearch #antibodies

Sullivan is financial advisors' counsel for A.G.P./Alliance Global Partners and Laidlaw & Company (UK) Ltd. in the $58.5 million announced merger agreement between Hepion Pharmaceuticals, Inc. and Pharma Two B Ltd. and the $2.9 million concurrent private placement of non-convertible senior notes. Hepion Pharmaceuticals (Nasdaq: HEPA) is a clinical-stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic diseases, hepatocellular carcinoma (“HCC”), and other chronic diseases. Pharma Two B Ltd. is a late-clinical stage private Israeli company that is developing P2B001, an innovative combination product candidate in development for the treatment of Parkinson’s Disease (“PD”). The Sullivan team consisted of David Danovitch and Aaron Schleicher, with assistance from Jiayin Liao. To read the press release, click here: https://lnkd.in/g27Vp8zs #WhatsYourNext #CapitalMarkets

Sullivan is financial advisors' counsel for A.G.P./Alliance Global Partners and Laidlaw & Company (UK) Ltd. in the $58.5 million announced merger agreement between Hepion Pharmaceuticals, Inc. and Pharma Two B Ltd. and the $2.9 million concurrent private placement of non-convertible senior notes. Hepion Pharmaceuticals (Nasdaq: HEPA) is a clinical-stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic diseases, hepatocellular carcinoma (“HCC”), and other chronic diseases. Pharma Two B Ltd. is a late-clinical stage private Israeli company that is developing P2B001, an innovative combination product candidate in development for the treatment of Parkinson’s Disease (“PD”). The Sullivan team consisted of David Danovitch and Aaron Schleicher, with assistance from Jiayin Liao. To read the press release, click here: https://lnkd.in/ec7yun-M #WhatsYourNext #CapitalMarkets

#VisionLead Oncology Drugs dominate the Pharmaceuticals market, and they're expected to keep growing, especially due to progress in immuno-oncology. However, these drugs are often expensive, mainly because there are only a few of them that are high-priced. Wealthier countries contribute most to the revenue, and for many big pharmaceutical companies, oncology is their primary market. Predictions suggest that the Oncology Drugs market will hit US$188.20 billion in revenue by 2023, and it's projected to grow annually at a rate of 13.95% (CAGR 2023-2028), reaching a market volume of US$361.60 billion by 2028.

New Week, New Fast Fact's Friday! Here are the Fast Facts for 1/12: - After two successful Phase 3 Trials, Astellas Pharma was positioned to have the first approved therapy for claudin (CLDN) positive tumors. However, the Japanese company must now clear up manufacturing issues, following a CRL from the FDA. Read more: (https://lnkd.in/eJM-6GCf) - Only a month after closing the $43 billion acquisition of Seagen, Pfizer continues to be on the hunt for antibody-drug conjugates (ADC) according to Chief Oncology Officer Chris Boshoff Read more: (https://lnkd.in/eGvNxSu3) - BioMarin Pharmaceutical Inc. CEO Alexander Hardy announces the departure of Chief Commercial Officer Jeffrey Ajer, in a shake-up looking to boost launch success for Voxzogo & Roctavian Read more: (https://lnkd.in/es_2NAMd) - After a few months of reports coming from the FDA's Adverse Event Reporting System (FAERS), a preliminary evaluation showed no evidence linking Novo Nordisk's & Eli Lilly and Company's GLP-1 treatments to suicidal thoughts & actions Read more: (https://lnkd.in/ePtrjjQ9) #pharma #biotech #meddevice #jpm2024